What is Mirdametinib?

What is Mirdametinib?

Mirdametinib is a prescription medicine specifically used to treat adults and pediatric patients aged 2 years and older who have neurofibromatosis type 1 (NF1) with symptomatic plexiform neurofibromas (PN). These are tumors that cause significant symptoms and cannot be completely removed by surgery. NF1 is a genetic disorder that causes non-cancerous tumors to grow along nerves throughout the body, and plexiform neurofibromas are the most common and most difficult-to-treat type. Mirdametinib is not a traditional chemotherapy drug; it is a targeted therapy called a MEK inhibitor. Its mechanism of action helps block certain abnormal signals in the body that promote the growth of plexiform neurofibromas, thereby inhibiting further tumor progression. For children under 2 years of age, it is not known whether Mirdametinib is safe or effective, so the drug is not approved for this age group. In February 2025, the U.S. FDA formally approved Mirdametinib for the treatment of NF1-PN in adults and children (aged 2 years and older), offering new hope for many patients whose tumors cannot be surgically removed. If you or a family member has been diagnosed with NF1-PN and the tumor cannot be completely resected, Mirdametinib may be a treatment option worth discussing with your doctor.

Health conditions to tell your doctor about before taking Mirdametinib

Before starting Mirdametinib, you must inform your healthcare provider of all your health conditions, as this is very important. First, if you have any eye problems, such as blurred vision, decreased vision, or other visual abnormalities, be sure to mention them, because Mirdametinib may cause or worsen eye disorders, which can be severe and even lead to blindness. Second, if you have heart problems, such as heart failure, irregular heart rhythms, or decreased pumping function of the heart, you should also tell your doctor, as Mirdametinib may reduce the heart's pumping capacity – this is especially common in children and can be serious. Additionally, if you are pregnant or planning to become pregnant, you must tell your doctor immediately, because Mirdametinib may harm an unborn baby. For women of childbearing potential, your doctor will perform a pregnancy test before treatment and require you to use effective contraception during treatment and for 6 weeks after the last dose. For men with female partners of childbearing potential, effective contraception is also required during treatment and for 3 months after the last dose. Also, if you are breastfeeding or planning to breastfeed, you should tell your doctor, as it is not known whether Mirdametinib passes into breast milk; therefore, breastfeeding is not recommended during treatment and for 1 week after the last dose. Finally, you should list all medications you are taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements, to avoid potential drug interactions.

Serious eye problems that Mirdametinib may cause

Mirdametinib may cause serious eye side effects, possibly even leading to blindness, so you need to be highly vigilant throughout treatment. Specifically, Mirdametinib may damage the retina or other ocular structures, causing blurred vision, partial or complete loss of vision, and other visual changes such as visual field defects, color vision abnormalities, or increased sensitivity to light. These eye problems can occur at any time after starting treatment; some patients may experience symptoms early in treatment. To minimize risk, your healthcare provider will perform a comprehensive eye examination before you start Mirdametinib to assess your baseline vision. During treatment, your doctor will schedule regular eye follow-ups, typically every 3 to 6 months, or anytime you experience visual abnormalities. If you develop any of the following symptoms during treatment, you must tell your doctor immediately: vision becomes blurred, double vision, floaters in your field of vision, narrowed visual field, sudden inability to see in a certain direction, or a significant decrease in vision over a short period. Do not wait until your next scheduled appointment, because prompt action may be key to preventing permanent vision damage. Depending on the severity of the eye problem, your doctor may decide to temporarily interrupt Mirdametinib treatment, reduce the dose, or permanently stop treatment. Additionally, you may be referred to an eye specialist for further evaluation and management.